Antony Blanc
Corporate Officer/Principal chez CUREVAC N.V.
Fortune : 7 781 $ au 31/03/2024
Profil
Antony Blanc is currently the Chief Business & Commercial Officer at CureVac NV since 2020.
Prior to this, he worked as the Chief Business Officer at Synosia Therapeutics AG from 2000 to 2009 and as the Head-Biopharma at Syngenta AG from 2000 to 2009.
He also worked at Mckinsey & Co., Inc. (Germany) as an Associate Partner from 2009 to 2017.
Dr. Blanc received his undergraduate and doctorate degrees from McGill University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CUREVAC N.V.
0,00% | 31/03/2023 | 2 568 ( 0,00% ) | 7 781 $ | 31/03/2024 |
Postes actifs de Antony Blanc
| Sociétés | Poste | Début |
|---|---|---|
| CUREVAC N.V. | Corporate Officer/Principal | 04/12/2020 |
Anciens postes connus de Antony Blanc
| Sociétés | Poste | Fin |
|---|---|---|
| Mckinsey & Co., Inc. (Germany) | Corporate Officer/Principal | 01/01/2017 |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Corporate Officer/Principal | 01/01/2009 |
| SYNGENTA | Corporate Officer/Principal | 01/01/2009 |
Formation de Antony Blanc
| McGill University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CUREVAC N.V. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Synosia Therapeutics AG
Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |
Syngenta AG
 Syngenta AG Chemicals: AgriculturalProcess Industries Syngenta AG specializes in crop protection and seeds production. Its products include selective and non-selective herbicides, fungicides, insecticides, as well as field crop and vegetable seeds. The company was founded on November 12, 1999 and is headquartered in Basel, Switzerland. | Process Industries |
| Mckinsey & Co., Inc. (Germany) |
